中华肝脏病杂志
中華肝髒病雜誌
중화간장병잡지
CHINESE JOURNAL OF HEPATOLOGY
2014年
10期
763-768
,共6页
药物断损伤%经济学,药学%决策树
藥物斷損傷%經濟學,藥學%決策樹
약물단손상%경제학,약학%결책수
Drug-induced liver injury%Economics,pharmaceutical%Decision trees
目的 评价4种常用保肝药物治疗药物性肝损伤的经济学效果.方法 构建决策分析模型,率值参数来源于文献资料的Meta分析结果,效果参数来源于专家意见,成本参数如使用规格、数量和单价来源于文献资料、专家意见、国家卫生和计划生育委员会与国家发展和改革委员会最新发布数据等.结果 4种用药方案中,双环醇组治疗效果(4.5118)最好、成本-效果比(86.2667)较小,增量成本-效果比(245.0118)最小且安全性最好;硫普罗宁肠溶片组治疗效果(4.1352)较差,但成本(296.9536)最低;以显效率作为产出计算,双环醇组显效率(73.10)最高,且成本-效果比(5.32)最低,增量成本效果比(4.93)最小.敏感度分析证实这一结果可靠.结论 双环醇可安全、有效的治疗药物性肝损伤,且具有成本效果优势.
目的 評價4種常用保肝藥物治療藥物性肝損傷的經濟學效果.方法 構建決策分析模型,率值參數來源于文獻資料的Meta分析結果,效果參數來源于專傢意見,成本參數如使用規格、數量和單價來源于文獻資料、專傢意見、國傢衛生和計劃生育委員會與國傢髮展和改革委員會最新髮佈數據等.結果 4種用藥方案中,雙環醇組治療效果(4.5118)最好、成本-效果比(86.2667)較小,增量成本-效果比(245.0118)最小且安全性最好;硫普囉寧腸溶片組治療效果(4.1352)較差,但成本(296.9536)最低;以顯效率作為產齣計算,雙環醇組顯效率(73.10)最高,且成本-效果比(5.32)最低,增量成本效果比(4.93)最小.敏感度分析證實這一結果可靠.結論 雙環醇可安全、有效的治療藥物性肝損傷,且具有成本效果優勢.
목적 평개4충상용보간약물치료약물성간손상적경제학효과.방법 구건결책분석모형,솔치삼수래원우문헌자료적Meta분석결과,효과삼수래원우전가의견,성본삼수여사용규격、수량화단개래원우문헌자료、전가의견、국가위생화계화생육위원회여국가발전화개혁위원회최신발포수거등.결과 4충용약방안중,쌍배순조치료효과(4.5118)최호、성본-효과비(86.2667)교소,증량성본-효과비(245.0118)최소차안전성최호;류보라저장용편조치료효과(4.1352)교차,단성본(296.9536)최저;이현효솔작위산출계산,쌍배순조현효솔(73.10)최고,차성본-효과비(5.32)최저,증량성본효과비(4.93)최소.민감도분석증실저일결과가고.결론 쌍배순가안전、유효적치료약물성간손상,차구유성본효과우세.
Objective To perform a pharmacoeconomic evaluation of the efficacies of therapeutic schemes involving four hepatoprotective drugs for the treatment of drug-induced liver injury (DILI).Methods The principle of decision tree analysis in pharmacoeconomics was applied to perform a retrospective analysis using a meta-analyses approach to evaluate the data from randomized controlled trials of four common therapeutic schemes.The key parameters for evaluating efficacy and safety of each were identified by searching the official data,relevant literature and expert opinions,and included the parameters of consumption and unit cost with respect to a variety of health resources.Results The hepatoprotective drug showing the greatest efficacy (4.5118) and safety for treating DILI was bicyclol; this drug also had a lower incremental cost-effectiveness ratio (ICER; 245.0118) than the other three therapeutic schemes.The tioproninenteric-coated tablet had the lowest cost (296.9536) among the four,but also had the worst efficacy (4.1352).Bicyclol had the lowest cost/benefit ratio (5.32) and ICER (4.93) among all the therapeutic schemes evaluated.Sensitivity analyses confirmed the robustness of these results.Conclusion According to this pharmacoeconomic evaluation,the bicyclol therapeutic strategy is the most cost-effective choice for DILI.
